

## Salah-Dine Chibout



### **Global Head of Discovery & Investigative Safety / Global Head of Therapeutic Areas (TAs) at Novartis Pharma AG in Basel, Switzerland**

Salah-Dine Chibout is the Global Head of Discovery & Investigative Safety (DIS) and Global Head Therapeutic Areas in Preclinical Safety (PCS) at Novartis Institutes for BioMedical Research (NIBR).

The DIS group focuses on problem solving and issue resolution related to drug safety during all phases of discovery and development of new medicines. He is responsible for a cross-functional global organisation operating from Cambridge, East Hanover and Basel.

The Preclinical Safety Therapeutic Areas are managing all Novartis projects from discovery to registration and consist in project team members representing PCS in early and late-phase project teams. They are preparing all relevant documentation for health authorities and respond to regulatory requests.

### **Previous and other positions**

Salah-Dine has more than 22 years of experience in drug development and obtained a PhD in molecular immunology from the Biozentrum in Basel, Switzerland. He joined Sandoz in 1990 in the Toxicology Department. From 2008 to 2010 he was deputy Head of Translational Science in Europe.

Salah-Dine represents Novartis at the Research of Director Board in the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is a Board Member of the Innovative Medicines Initiatives (IMI), which is the largest public-private partnership with the European Commission.